Table 1.
Demographic and Clinical Parameters of patients with IIIA/N2 NSCLC
| Characteristics | No surgery or Radiotherapy (n = 5512) |
Surgery only (n = 7184) |
Preoperative radiotherapy (n = 652) |
Postoperative radiotherapy (PORT, n = 4206) |
Radiotherapy both before and after surgery(n = 100) | P value for X2 |
|---|---|---|---|---|---|---|
| Gender | <0.001 | |||||
| Male | 2572(46.66%) | 3680(51.22%) | 329(50.46%) | 2152(51.17%) | 53(53.00%) | |
| Female | 2940(53.34%) | 3504(48.78%) | 323(49.54%) | 2054(48.83%) | 47(47.00%) | |
| Age | <0.001 | |||||
| < =75 | 3893(70.63%) | 4940(68.76%) | 608(93.25%) | 3567(84.81%) | 92(92.00%) | |
| > 75 | 1619(29.37%) | 2244(31.24%) | 44(6.75%) | 639(15.19%) | 8(8.00%) | |
| Histologic type | <0.001 | |||||
| Adenocarcinoma | 2081(37.75%) | 3831(53.33%) | 342(52.45%) | 2486(59.11%) | 65(65.00%) | |
| Squamous | 2118(38.43%) | 1922(26.75%) | 173(26.53%) | 1003(23.85%) | 19(19.00%) | |
| Adenosquamous | 67(1.22%) | 158(2.20%) | 17(2.61%) | 88(2.09%) | 1(1.00%) | |
| Large cell | 144(2.61%) | 201(2.80%) | 23(3.53%) | 129(3.07%) | 1(1.00%) | |
| OTHER | 1102(19.99%) | 1072(14.92%) | 97(14.88%) | 500(11.89%) | 14(14.00%) | |
| Tumor Size (cm) | <0.001 | |||||
| ≤ 3 | 2318(42.05%) | 3765(52.41%) | 295(45.25%) | 2483(59.03%) | 47(47.00%) | |
| 3–5 | 3194(57.95%) | 3419(47.59%) | 357(54.85%) | 1723(40.97%) | 53(53.00%) | |
| Race | <0.001 | |||||
| White | 4444(80.62%) | 5810(80.87%) | 544(83.44%) | 3436(81.69%) | 78(78.00%) | |
| Black | 763(13.84%) | 802(11.16%) | 68(10.43%) | 482(11.46%) | 9(9.00%) | |
| Others | 297(5.39%) | 553(7.70%) | 40(6.13%) | 281(6.68%) | 13(13.00%) | |
| Unknown | 8(0.15%) | 19(0.27%) | 0(0.00%) | 7(0.17%) | 0(0.00%) | |
| Primary Site | <0.001 | |||||
| Upper lobe | 3454(62.66%) | 4302(59.88%) | 447(68.56%) | 2628(62.48%) | 65(65.00%) | |
| Middle lobe | 241(4.37%) | 326(4.54%) | 34(5.21%) | 226(5.37%) | 5(5.00%) | |
| Lower lobe | 1337(24.26%) | 2141(29.80%) | 138(21.17%) | 1098(26.11%) | 27(27.00%) | |
| NOS | 155(2.81%) | 195(2.71%) | 9(1.38%) | 123(2.92%) | 0(0.00%) | |
| Overlapping lesion | 33(0.60%) | 64(0.89%) | 6(0.92%) | 28(0.67%) | 2(2.00%) | |
| Main bronchus | 292(5.30%) | 156(2.17%) | 18(2.76%) | 103(2.45%) | 1(1.00%) | |
| Grade | <0.001 | |||||
| Grade I | 154(2.79%) | 327(4.55%) | 23(3.53%) | 138(3.28%) | 3(3.00%) | |
| Grade II | 900(16.33%) | 1935(26.93%) | 138(21.17%) | 1021(24.27%) | 26(26.00%) | |
| Grade III | 1722(31.24%) | 2427(33.78%) | 278(42.64%) | 1361(32.36%) | 39(39.00%) | |
| Grade IV | 83(1.51%) | 122(1.70%) | 5(0.77%) | 62(1.47%) | 3(3.00%) | |
| unknown | 2653(48.13%) | 2373(33.03%) | 208(31.90%) | 1624(38.61%) | 29(29.00%) | |
| Laterality | 0.001 | |||||
| Right-origin of primary | 3421(62.06%) | 4316(60.08%) | 405(62.12%) | 2631(62.55%) | 67(67.00%) | |
| Left-origin of primary | 2063(37.43%) | 2840(39.53%) | 246(37.73%) | 1531(36.40%) | 33(33.00%) | |
| Paired sit | 23(0.42%) | 20(0.28%) | 1(0.15%) | 38(0.90%) | 0(0.00%) | |
| Only one side - side unspecified | 4(0.07%) | 6(0.08%) | 0(0.00%) | 4(0.10%) | 0(0.00%) | |
| Not a paired site | 1(0.02%) | 2(0.03%) | 0(0.00%) | 2(0.05%) | 0(0.00%) | |
| Insurance status | <0.001 | |||||
| Medicaid | 594(10.78%) | 768(10.70%) | 45(6.90%) | 399(9.49%) | 7(7.00%) | |
| Uninsured | 101(1.83%) | 118(1.65%) | 10(1.53%) | 59(1.40%) | 2(2.00%) | |
| Unknown | 1316(23.88%) | 1858(25.86%) | 180(27.61%) | 847(20.14%) | 29(29.00%) | |
| Insured | 3501(63.52) | 4440(61.80%) | 417(63.96%) | 2901(68.97%) | 62(62.00%) | |
| Marital status | <0.001 | |||||
| Married | 2812(51.02%) | 3644(50.72%) | 393(60.28%) | 2440(58.01%) | 58(58.00%) | |
| Single | 671(12.17%) | 887(12.35%) | 76(11.66%) | 467(11.10%) | 12(12.00%) | |
| Divorced | 681(12.35%) | 903(12.57%) | 93(14.26%) | 540(12.84%) | 12(12.00%) | |
| widowed | 1079(19.6%) | 1401(19.50%) | 63(9.66%) | 574(13.65%) | 11(11.00%) | |
| Unknown | 181(3.28%) | 262(3.65%) | 20(3.07%) | 131(3.11%) | 1(1.00%) | |
| Unmarried or domestic partner | 6(0.11%) | 12(0.17%) | 1(0.15%) | 12(0.29%) | 0(0.00%) | |
| Separated | 82(1.49%) | 75(1.04%) | 6(0.92%) | 42(1.00%) | 6(6.00%) | |
| Year of diagnosis | <0.001 | |||||
| 2004–2007 | 1756(31.86%) | 2399(33.39%) | 241(36.96%) | 1105(26.27%) | 37(37.00%) | |
| 2008–2011 | 1982(35.96%) | 2437(33.92%) | 216(33.13%) | 1326(31.53%) | 35(35.00%) | |
| 2012–2017 | 1774(32.18%) | 2348(32.68%) | 195(29.91%) | 1775(42.20%) | 28(28.00%) | |
| Region | <0.001 | |||||
| EAST | 2733(49.58%) | 3243(45.14%) | 283(43.40%) | 2148(51.07%) | 38(38.00%) | |
| NORTHWEST | 1965(35.65%) | 3082(42.90%) | 265(40.64%) | 1417(33.69%) | 50(50.00%) | |
| SOUTHWEST | 661(11.99%) | 647(9.01%) | 86(13.19%) | 561(13.34%) | 10(10.00%) | |
| Pacific Coast | 153(2.78%) | 212(2.95%) | 18(2.76%) | 80(1.90%) | 2(2.00%) | |
| High school education | <0.001 | |||||
| ≥ 21 | 977(17.72%) | 1524(21.21%) | 102(15.64%) | 590(14.03%) | 19(19.00%) | |
| 13–20 | 1823(33.07%) | 2293(31.92%) | 159(24.39%) | 1199(28.51%) | 32(32.00%) | |
| 7–12.99 | 2363(42.87%) | 2968(41.31%) | 344(52.76%) | 2101(49.95%) | 41(41.00%) | |
| < 7 | 349(6.33%) | 399(5.55%) | 47(7.21%) | 316(7.51%) | 8(8.00%) | |
| Median household income, in tens | <0.001 | |||||
| < 38,000 | 422(7.66%) | 570(7.927%) | 28(4.29%) | 290(6.89%) | 5(5.00%) | |
| 38,000–47,999 | 1080(19.59%) | 1097(15.27%) | 88(13.50%) | 731(17.38%) | 14(14.00%) | |
| 48,000–62,999 | 2064(37.45%) | 2842(39.56%) | 276(42.33%) | 1588(37.76%) | 40(40.00%) | |
| > 63,000 | 1946(35.30%) | 2675(37.24%) | 260(39.88%) | 1597(37.97%) | 41(41.00%) | |
| Chemotherapy | <0.001 | |||||
| Yes | 4221(76.58%) | 3184(44.32%) | 631(96.78%) | 3791(90.13%) | 96(96.00%) | |
| no | 1291(23.42%) | 4000(55.68%) | 21(3.22%) | 415(9.87%) | 4(4.00%) | |
Abbreviations: NSCLC Non-small cell lung cancer, IIIA/N2 Stage IIIA pathologic N2